Infectious Disease and Microbiology – Morganella morganii

Overview

Morganella morganii is an aerobic Gram-negative bacillus in the Enterobacterales group that is widely distributed and most often causes opportunistic healthcare-associated infections.

It is particularly associated with urinary tract infection, pneumonia, bacteremia, and sepsis, especially in hospitalized or medically complex patients. It may also be present in the mouths of snakes and can occasionally contribute to infection after snake bites.

⸻

Classification

Genus: Morganella

Species: Morganella morganii

Type: Aerobic Gram-negative bacillus

Order: Enterobacterales

⸻

Microbiologic Characteristics

M. morganii is generally:

• Gram-negative

• Rod-shaped

• Facultatively anaerobic despite the source describing it as aerobic

• Motile

• A member of the normal intestinal flora in humans and animals

It is related microbiologically to organisms such as:

• Proteus

• Providencia

⸻

Incubation Period

The incubation period is:

Unknown

Because most infections are endogenous or healthcare-associated, a specific incubation period is usually not defined.

⸻

Epidemiology

Morganella morganii occurs:

Worldwide

It is generally a low-virulence organism but can become pathogenic in the presence of:

• Hospitalization

• Indwelling urinary catheters

• Advanced age

• Immunosuppression

• Recent surgery

• Broad-spectrum antibiotic exposure

• Other severe underlying illness

⸻

Nosocomial Infection

The source emphasizes that M. morganii most commonly causes:

Healthcare-associated infection

Important sites include:

• Urinary tract

• Respiratory tract

• Bloodstream

• Wounds

⸻

Urinary Tract Infection

One of the most common clinical manifestations is:

Urinary tract infection

This is especially associated with:

• Urinary catheterization

• Structural urinary tract disease

• Prolonged hospitalization

⸻

Urease Production

M. morganii is:

Urease positive

This can contribute to:

Alkaline urine

and may promote urinary crystal or stone formation in some patients.

⸻

High-Yield Urinary Pattern

Hospitalized patient

Urinary catheter

Gram-negative bacillus

Urease positivity

→ Consider Morganella morganii, Proteus, or Providencia

⸻

Pulmonary Infection

M. morganii may cause:

Pneumonia

particularly in:

• Hospitalized patients

• Patients with chronic illness

• Ventilated patients

• Immunocompromised hosts

Pulmonary infection is usually healthcare-associated rather than community-acquired.

⸻

Bacteremia and Sepsis

M. morganii can enter the bloodstream and cause:

Bacteremia

or

Sepsis

Common sources include:

• Urinary tract

• Intra-abdominal infection

• Wounds

• Respiratory tract

Severe infection is more likely in medically fragile patients.

⸻

Snake Bite-Associated Infection

The source notes that M. morganii may be found in:

Snake oral flora

Therefore, it can occasionally contribute to:

Secondary infection of snake bite wounds

These infections are often polymicrobial.

⸻

Clinical Implication

After a snake bite, wound infection may involve:

• Morganella

• Aeromonas

• Enteric Gram-negative bacilli

• Anaerobic organisms

The exact microbiology depends on the snake species and environmental exposure.

⸻

Diagnosis

The primary diagnostic method is:

Culture

Relevant specimens may include:

• Urine

• Blood

• Respiratory secretions

• Wound material

• Other normally sterile body fluids

⸻

Laboratory Identification

M. morganii may be identified using:

• Routine biochemical testing

• Automated microbiology systems

• MALDI-TOF mass spectrometry

Susceptibility testing is particularly important because resistance patterns can vary.

⸻

Antibiotic Resistance

An important feature of M. morganii is the presence of:

Chromosomal AmpC beta-lactamase

This can confer resistance to several beta-lactam antibiotics and may lead to resistance emerging during therapy.

⸻

AmpC Clinical Significance

AmpC activity may reduce susceptibility to:

• Ampicillin

• Amoxicillin

• First-generation cephalosporins

• Some later-generation cephalosporins

For serious infection, treatment should be based on:

Antimicrobial susceptibility results

⸻

High-Yield Resistance Pattern

Morganella morganii

Enterobacterales organism

AmpC beta-lactamase potential

→ Be cautious with cephalosporins in serious infections

⸻

Treatment

The source lists:

• Carbapenems, including imipenem and meropenem

• Ciprofloxacin

These may be appropriate for susceptible isolates, especially in severe infection.

⸻

Additional Treatment Options

The source also lists:

• Third-generation cephalosporins

• Aztreonam

• Ofloxacin

• Piperacillin–tazobactam

• Aminoglycosides

However, resistance is increasingly important, so therapy should be:

Susceptibility guided

⸻

Third-Generation Cephalosporins

The source specifically notes:

Increasing resistance

with third-generation cephalosporins.

Because inducible or derepressed AmpC beta-lactamase activity can occur, these drugs may be unreliable in some serious infections.

⸻

Treatment Principle

Severe M. morganii infection

↓

Obtain cultures

↓

Perform susceptibility testing

↓

Select active antimicrobial therapy

↓

Address source control

This may include:

• Removing infected catheters

• Draining abscesses

• Managing obstructed urinary systems

• Debriding infected wounds when necessary

⸻

Morganella vs. Proteus

Morganella morganii

→ Gram-negative rod

→ Urease positive

→ Nosocomial UTI and sepsis

→ Motile

→ AmpC beta-lactamase potential

→ Does not typically produce the dramatic swarming pattern associated with Proteus

Proteus mirabilis

→ Gram-negative rod

→ Strongly urease positive

→ Swarming motility

→ UTI and struvite stones

→ Characteristic fishy odor may occur

⸻

Morganella vs. Providencia

Morganella

→ Healthcare-associated UTI

→ Sepsis

→ Urease positive

→ AmpC-associated resistance

Providencia

→ Particularly associated with long-term urinary catheters

→ UTI and bacteremia

→ Often multidrug resistant

Both belong to the Proteeae group and may have overlapping clinical settings.

⸻

High-Yield Clinical Pattern

Hospitalized or catheterized patient

UTI, pneumonia, or sepsis

Gram-negative bacillus

Urease positive

Potential AmpC resistance

→ Think Morganella morganii

⸻

Exam Essentials

Genus: Morganella

Species: M. morganii

Type: Gram-negative bacillus

Order: Enterobacterales

Motility: Motile

Urease: Positive

Distribution: Worldwide

Typical setting: Nosocomial/opportunistic infection

Major infections: UTI, pneumonia, bacteremia, sepsis

Special exposure: Snake bite wounds

Diagnosis: Culture

Resistance mechanism: Chromosomal AmpC beta-lactamase

Source treatment: Carbapenem or ciprofloxacin

Other options: Piperacillin–tazobactam, aztreonam, fluoroquinolones, aminoglycosides, selected cephalosporins

Treatment principle: Use susceptibility-guided therapy, particularly for severe infection

⸻

Key clinical pearl: Morganella morganii is a urease-positive opportunistic Gram-negative rod that commonly causes healthcare-associated UTI and sepsis. Its ability to express AmpC beta-lactamase makes resistance an important treatment consideration, so serious infections should be managed with susceptibility-guided therapy and appropriate source control.